Errata: Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy (Blood (2015) 126, 2 (222-232))

Byung Sik Cho, Zhihong Zeng, Hong Mu, Zhiqiang Wang, Sergej Konoplev, Teresa McQueen, Marina Protopopova, Jorge Cortes, Joseph R. Marszalek, Sheng Bin Peng, Wencai Ma, R. Eric Davis, Donald E. Thornton, Michael Andreeff, Marina Konopleva

Research output: Contribution to journalComment/debate

Original languageEnglish (US)
Number of pages1
JournalBlood
Volume126
Issue number8
DOIs
StatePublished - Aug 20 2015
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Cho, B. S., Zeng, Z., Mu, H., Wang, Z., Konoplev, S., McQueen, T., Protopopova, M., Cortes, J., Marszalek, J. R., Peng, S. B., Ma, W., Davis, R. E., Thornton, D. E., Andreeff, M., & Konopleva, M. (2015). Errata: Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy (Blood (2015) 126, 2 (222-232)). Blood, 126(8). https://doi.org/10.1182/blood-2015-07-657387